All News

Found 636,589 articles

• Notice to the media - COVID-19 Update (November 27, 2020) - Ministers and Government of Canada officials to hold a news conference on coronavirus disease

  11/27/2020

  - Ministers and Government of Canada officials will hold a news conference to provide an update on coronavirus disease (COVID-19). Date November 27, 2020 Time 12:00 PM (EST) Location Sir John A Macdonald Building, Room 200 144 Wellington Street, Ottawa, Ontario The media availability will also be held by teleconferenc

• Strengthening Canada's response to food safety issues

  11/27/2020

  The Government of Canada has officially launched the Canadian Food Safety Information Network (CFSIN) , a new food safety platform that will help food safety experts from across the country work together to better anticipate, detect and respond to food safety issues and foodborne illness incidents. The newly up and running network is

• WestJet-YVR COVID-19 Testing Study Launches

  11/27/2020

  oday marked the launch of the WestJet-YVR COVID-19 Testing Study, a collaborative effort between researchers from UBC and Providence Health Care and project sponsors WestJet and Vancouver Airport Authority.

• AHF Backs Proposal to Ease Tariffs on COVID-19 Drugs

  11/27/2020

  AIDS Healthcare Foundation, the world’s largest global AIDS organization, supports a proposal sent to the World Trade Organization by the EU and 13 other countries to remove impediments to trade in essential medical goods. LOS ANGELES--( BUSINESS WIRE )-- A block of 13 World Trade Organization (WTO) member countries and the EU, known as the Ottawa Group , issued a proposal on Monday urging other WTO members to refrain from imposing tariffs and expo

• Major-General Dany Fortin assisting Government of Canada's vaccine distribution planning

  11/27/2020

  - Canada is well positioned to obtain COVID-19 vaccines because of ongoing preparation over the last months. This work to provide every Canadian with access to a vaccine continues, and today, the Honourable Patty Hajdu, Minister of Health, and the Honourable Harjit S. Sajjan , Minister of National Defence, announced that Major-General Dany Fo

• Advaxis, Inc. Announces Closing of $9.2 Million Public Offering

  11/27/2020

  PRINCETON, N.J., Nov. 27, 2020 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS) (the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today announced the closing of an underwritten public offering of 26,666,666 shares of common stock and warrants to purchase up to 13,333,333 shares of common stock, along with an additional 3,999,999 shares of common stock and 1,999,999 warrants pursuant to the full exercise of the

• Xeris Pharmaceuticals Announces Grants Under NASDAQ Listing Rule 5635(c)(4)

  11/27/2020

  Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today announced that on November 25, 2020, the Compensation Committee of Xeris’ Board of Directors granted non-qualified stock options for an aggregate of 18,000 shares, and restricted stock units for an aggregate of 70,200 s

• Acerus Announces Details of Previously Completed Rights Offering

  11/27/2020

  Acerus Pharmaceuticals Corporation (“ Acerus ” or the “ Company ”) (TSX: ASP, OTCQB: ASPCF) is pleased to announce that, further to its press release dated November 25, 2020 with respect to the completion of Acerus’ rights offering (the “ Rights Offering ”), Acerus issued 526,600,000 common shares of Acerus (“ Common Shares ”) under the Rights Offering at a price of $0.025 per share for gross proceeds of approximately $13,165,

• Rhythm Pharmaceuticals Announces FDA Approval of IMCIVREE™ (setmelanotide) as First-ever Therapy for Chronic Weight Management in Patients with Obesity Due to POMC, PCSK1 or LEPR Deficiency

  11/27/2020

  -- Indicated for chronic weight management in adult and pediatric patients 6 years of age and older with obesity due to POMC, PCSK1 or LEPR deficiency confirmed by genetic testing -- -- Approval supports company’s approach to address rare genetic diseases of obesity associated with an impaired MC4 receptor pathway -- -- People living with these rare genetic diseases of obesity struggle with insatiable hunger and excessive weight gain beginning at a young age --

• Calliditas Therapeutics' nomination committee for the AGM 2021

  11/27/2020

  Calliditas Therapeutics AB (publ.) publishes the nomination committee's composition for the AGM in 2021.   The nomination committee, which is appointed in accordance with the principles adopted by the extraordinary general meeting on September 14, 2017 , consists of: · Patrick Sobocki, appointed by Stiftelsen Industrifonden

• Eluminex Biosciences, an Ophthalmology-Focused Biotechnology Company, Announces Closing of $50 Million Series A Financing

  11/27/2020

    [27-November-2020]   Proceeds to fund development of novel and best-in-class therapeutics for eye diseases Charles Semba , MD, joins the company to serve as Chief Medical Officer

• 4D pharma plc Files SEC Forms in Process to Gain NASDAQ Listing Following Merger with Longevity, a Special Purpose Acquisition Company (SPAC)

  11/27/2020

  Merger completion and NASDAQ listing expected in Q1 2021 US listing will support and accelerate ongoing development of 4D pharma’s Live Biotherapeutics

• Exelixis Announces Partner Takeda Receives Approval in Japan for CABOMETYX® (cabozantinib) for the Treatment of Unresectable Hepatocellular Carcinoma That Has Progressed After Prior Systemic Therapy

  11/27/2020

  Exelixis Announces Partner Takeda Receives Approval in Japan for CABOMETYX® (cabozantinib) for the Treatment of Unresectable Hepatocellular Carcinoma That Has Progressed After Prior Systemic Therapy — Approval based on results of two clinical trials in patients with advanced hepatocellular carcinoma who had received prior systemic therapy — ALAMEDA, Calif.--( BUSINESS WIRE )-- Exelixis, Inc. (NASDAQ: EXEL) today announced that Takeda Pharmaceuti

• Enova Illumination Introduces LED Light for Loupes and Face Shields to Advance Comfort and Visualization in Dentistry, Oral Surgery and Cosmetic Dermatology

  11/27/2020

  Enova Illumination introduced today the new Axis™ LED Light with Activ™ Battery System, the first LED light solution to pair a clip-on magnetic light with a wearable neckband battery for improv

• Overjet Tapped by AEGIS for Dental Artificial Intelligence Article Series

  11/27/2020

  Overjet Inc, the leading provider of artificial intelligence (AI) for the dental community, was selected by AEGIS to share a curated series on how AI is transforming dentistry. The series will appear in Compendium in 2021

• Genetron Health Provides Update on HCCscreen™ for Liver Cancer Early Screening in China

  11/27/2020

  Genetron Health Provides Update on HCCscreen™ for Liver Cancer Early Screening in China HCCscreen TM was selected by the National Cancer Center and the Wuxi municipal government for use in the “Liver Cancer Early Screening Comprehensive Prevention and Control Project”, a public health initiative Establishes joint venture with Wuxi municipal government; Expects the commercialization and revenues of HCCscreen TM to accelerate in China

• USAN Modifies Lead Drug Candidate’s Chemical Name to ‘Simufilam’Future References to Lead Drug Candidate for Alzheimer’s Disease Will Be Simufilam

  11/27/2020

  Cassava Sciences, Inc. (Nasdaq: SAVA) today announced that the World Health Organization (WHO) advised the United States Adopted Names Council (USAN) to modify the chemical name of the Company’s lead drug candidate to ‘simufilam.’ This change was advised by WHO to avoid a potential trademark conflict with a drug marketed in the Far East. USAN has accepted WHO’s advice. Future references to Cassava Sciences’ lead drug candidate for Alzheimer’s

• Hancock Jaffe Announces Reverse Stock Split

  11/27/2020

  Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI), a developer of medical devices that restore cardiac and vascular health, today announced that the companys Board of Directors has approved a reverse stock split of its shares of common stock at a ratio of 1 for 25. The Reverse Stock Split will become effective at 12:01 a.m. Eastern time on November 30, 2020 and the Companys common stock will open for tr

• Ceapro Inc. Reports 2020 Third Quarter and Nine-Month Financial Results and Operational Highlights

  11/27/2020

  – R&D activities focused on advancing the development of innovative delivery systems and yeast beta glucan as a potential inhalable therapeutic for COVID-19 – – Q3 2020 sales of $ 3,4 7 6,000 compared to $ 2,908 ,000 for Q3 2019, representing a 20 % increase – – Net profit of $ 192 ,000 for Q 3 2020 vs. net loss of $ 104 ,000 for Q 3 2019 – – Cash generated from operations of $ 4,777 ,000 in 2020 vs . $ 1,321 ,000 in 2019 – –

• Tauriga Sciences Inc. Sets New Daily E-Commerce Records for Both: Revenue Generated [$9,514.49] and Individual Online Orders [103 Total]

  11/27/2020

  Tauriga Sciences, Inc. (OTCQB: TAUG) (“Tauriga” or the “Company”), a revenue generating, diversified life sciences company, with a proprietary line of functional “supplement” chewing gums (Flavors: Pomegranate, Blood Orange, Peach-Lemon, Pear Bellini, Mint, Black Currant) as well as two ongoing Biotechnology initiatives, today reported re